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Abstract
This study examined Pre-Exposure Prophylaxis (PrEP) acceptability among female sex workers,
male-to-female transgendered persons, and men who have sex with men in Lima, Peru. Focus
groups explored social issues associated with PrEP acceptability and conjoint analysis assessed
preferences among eight hypothetical PrEP scenarios with varying attribute profiles and their
relative impact on acceptability. Conjoint analysis revealed that PrEP acceptability ranged from
19.8 to 82.5 out of a possible score of 100 across the eight hypothetical PrEP scenarios. Out-of-
pocket cost had the greatest impact on PrEP acceptability (25.2, p <0.001), followed by efficacy
(21.4, p <0.001) and potential side effects (14.7, p <0.001). Focus group data supported these
findings, and also revealed that potential sexual risk disinhibition, stigma and discrimination
associated with PrEP use, and mistrust of health care professionals were also concerns. These
issues will require careful attention when planning for PrEP roll-out if proven efficacious in
ongoing clinical trials.
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INTRODUCTION
The HIV prevention field continues to seek both behavioral and biomedical interventions to
reduce the transmission of HIV.1 Behavioral interventions have not been able to contain the
pandemic2 and recent biomedical approaches such as the use of the topical vaginal
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microbicides have had disappointing results.3 Pre-Exposure Prophylaxis (PrEP) is a
biomedical approach generating considerable interest, and could be an important additional
HIV prevention tool.2, 4-8 PrEP involves taking antiretroviral medications (ARVs) before
potential HIV exposure to prevent infection in contrast to Post-exposure Prophylaxes (PEP),
the use of ARVs after exposure to prevent infection. In practice, PrEP becomes PEP once
exposure occurs; however, for convenience we use the term “PrEP” to encompass the
regular use of ARVs by seronegative individuals to prevent HIV infection independent of
potential exposure. Currently, ARVs are used to prevent mother-to-child transmission of
HIV during childbirth9, 10 but the efficacy of their daily use among HIV-uninfected
individuals to prevent HIV infection during sexual intercourse is not yet known and is the
subject of multiple international studies, including Botswana (young adults), Thailand
(injection drug users), and Ecuador, Peru, Brazil and the United States (men who have sex
with men: MSM).2, 8, 11-13 In the Peru study, a daily dose of the ARVs emtricitabine and
tenofovir disoproxil fumarate, coformulated into one pill that is marketed as Truvada, is
being tested.
As the clinical trials work to establish PrEP clinical efficacy, a parallel body of research is
investigating its acceptability among potential users. For example, studies among MSM in
California and New York found that overall knowledge of PrEP was modest, with concerns
related to potential side effects and degree of effectiveness.8, 14, 15 There are no published
studies of which we are aware that examine PrEP acceptability among non-US populations,
who account for 96% of adults and children living with HIV globally.16
The purpose of this pilot study was to examine PrEP acceptability among female sex
workers (FSW), male-to-female transgendered persons (TG), and MSM in Lima, Peru.
These groups, when compared to the general population (HIV prevalence < 1%16), are at
elevated risk for HIV infection with HIV prevalences of 1.6%17 and potentially has high as
4.7%18 among FSW and 18-22% among MSM/ TG.16 Since PrEP clinical trials are
underway in Peru, data regarding its acceptability and potential impact on HIV risk
behaviors is needed in order to plan for roll-out should the strategy prove efficacious. To
address this, we conducted focus groups and conjoint analyses with the above three at-risk
populations; implications of our findings on future PrEP dissemination strategies in Peru are
discussed.
MATERIAL AND METHODS
Participants
Recruitment was based on convenience sampling, and was conducted by community Peer
Outreach Workers who went to venues such as parks, beauty salons, volley-ball courts and
certain community-based organizations in Lima where FSW, TG, and MSM were known to
frequent. The Peer Outreach Workers explained the study to potential participants and
referred those interested to the study staff. Participants were compensated 15 Nuevos Soles
(approx. USD 5.00) for transportation. Institutional Review Boards at the University of
California, Los Angeles and the Universidad Peruana Cayetano Heredia reviewed and
approved the study prior to implementation.
Procedures
Seven groups of 4-8 individuals (total n = 45) were formed (3 FSW, 2 TG, and 2 MSM).
Each group met once for approximately two hours when focus groups and conjoint analyses
were conducted. The focus groups were conducted prior to the conjoint analysis exercise as
it allowed for participants to freely discuss their understanding and knowledge of PrEP and
gave the facilitators the chance to correct any erroneous information about PrEP before the
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conjoint analysis exercise so that all participants were completing the exercise with the
same, correct information. Both procedures were conducted in Spanish by two, female,
bilingual (Spanish-English) masters-level facilitators who have extensive experience
working with our target population.
Focus Groups—Group facilitators led participants through a 45-minute discussion about
PrEP using a semi-structured guide (Table 1) examining general knowledge and awareness;
social and community concerns; ideal characteristics of PrEP; and possible behavioral
changes as a result of PrEP, patterned after similar work our group completed on HIV
vaccine acceptability. 19 The following description of PrEP was given to ensure that all
participants understood the approach and could differentiate it from PEP: “PrEP is a
hypothetical approach currently under investigation that involves HIV-negative individuals
taking ARVs daily in order to reduce the chance of HIV infection should he/she be exposed
to the virus.” ARV’s were described as medications for the treatment of HIV.Participants
were asked to discuss both their own opinions of PrEP as well as their perceptions of the
opinions and attitudes of their peers. Basic demographic information was collected at the
conclusion of the discussion.
Focus groups were recorded, transcribed and translated into English for the US-based
research team. The English transcript was then back-translated to Spanish by a second, blind
translator and compared to the original Spanish transcript in order to confirm its fidelity. To
increase reliability, two investigators (one from Lima and one from Los Angeles)
independently coded the transcripts and reviewed the codes with a third investigator.20 After
several iterations, 20 codes in 6 “families” (key themes) were created using ATLAS.ti 5.0.21
Analysis was further refined by identifying the most frequently occurring themes for each of
the three target populations.
Conjoint Analysis—We used conjoint analysis to assess the acceptability of hypothetical
PrEP scenarios and to quantify the impact of various PrEP attributes on acceptability.
Conjoint analysis is often used to elicit consumer preferences and has been widely applied in
economics and market research22-25 and is gaining popularity in the health domain for
assessing consumer acceptability of health care services25-27 and pharmaceuticals24-25.. In
this study, conjoint analysis was used to describe PrEP as a “bundle” of attributes.
Participants rated composite hypothetical PrEP scenarios, thus requiring decisions regarding
the relative importance of different PrEP attributes, which more closely approximates real
world decision-making than a series of disparate single item questions. Our group has
successfully used conjoint analysis to assess HIV vaccine acceptability28-29 and willingness
to participate in HIV vaccine trials.30 Seven PrEP attributes were identified by integrating
input from PrEP experts, PrEP acceptability research8, 14 and the need to present meaningful
alternatives from a consumer perspective.23,27,31
PrEP attributes were out of pocket cost per month (USD $10 vs. $250), efficacy (75% vs.
95%), side effects (none vs. nausea/dizziness), duration of use (1 year vs. 10 years), dosing
frequency (before sex vs. every day), dispensing venue (general clinic vs. HIV clinic), and
person dispensing (pharmacist vs. doctor/nurse). The range of cost was chosen to be
sufficient to produce an impact on acceptability. We selected 75% versus 95% efficacy
because the literature suggests that our target population expects PrEP to be completely
efficacious, thus our objective was to determine the effect of partial efficacy (75%) versus
almost complete efficacy (95%) on acceptability.8,14 The 1 year versus 10 years
administration of duration was selected to assess preferences regarding short term use of
PrEP (1 year) versus long term use (10 years).
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A full factorial design for eight PrEP scenarios, each with seven dichotomous attributes,
would yield 128 different PrEP scenarios (27 = 128). We applied a fractional factorial
orthogonal design to reduce the number to eight hypothetical PrEP scenarios.32
Following the focus groups, the hypothetical PrEP scenarios were presented simultaneously
to each individual participant on laminated cards. Participants rated their likelihood of
accepting each PrEP scenario on a 5-point Likert-type scale ranging from “definitely would
accept” to “definitely would not accept.” Ratings were transformed into a 0 to 100 scale,
whereby “definitely would accept”=100 and “definitely would not accept= 0.
We derived the acceptability of each hypothetical scenario by averaging individual PrEP
acceptability ratings across respondents. Next, a one-way analysis of variance (ANOVA)
model was applied to fit each respondent’s acceptability ratings across the 8 PrEP scenarios.
The 7 PrEP attributes served as independent variables in the model. The effect for each PrEP
attribute from the ANOVA model is the impact score of the attribute on PrEP acceptability
for the individual respondent. We then averaged individual impact scores across respondents
for each attribute to compute its impact on overall PrEP acceptability. A one-sample t-test
was used to determine the statistical significance of the impact of each attribute on PrEP
acceptability.
RESULTS
Demographics
We recruited 45 participants comprising 15 FSW in 3 groups, 13 TG in 2 groups, and 17
MSM in 2 groups. The mean age of participants was 40 (FSW), 28 (TG), and 33 (MSM).
Focus Groups
Six key themes were identified regarding PrEP: Knowledge/Awareness; Attitudes/
Expectations; Social/Community Concerns; Concerns regarding Health Care Professionals;
Ideal Characteristics; and Behavioral Changes. Results are organized by theme; see Table 2
for representative quotes.
PrEP knowledge/awareness—All three populations reported little or no knowledge/
awareness of PrEP, although one transgendered participant had heard of preparations for a
PrEP study in Peru (Quote 1).
PrEP attitudes/expectations—All three populations were generally supportive of using
PrEP, however, there were concerns regarding the need for a daily regimen and
remembering to take the pills (Quotes 2, 3) or the necessity to take the pills daily if not
regularly having sexual relations (Quote 4). Side effects were a concern among FSW and
TG participants, particularly with regards to other concomitant health conditions (Quotes 5,
6). MSM suggested that lifestyle issues such as going to a party and alcohol use could
interfere with taking PrEP (Quote 7). All three populations expressed high expectations for
PrEP as a method of self-care (Quote 8), as back-up protection when condoms are forgotten
or break (Quote 9), or for casual sex (Quote 10).
Social and community concerns regarding PrEP use—All groups were supportive
of selective disclosure of PrEP use within their specific social networks, for example to
other sex workers (Quote 11) or friends (Quotes 12, 13), while disclosure of use to clients or
one-night stands was not supported (Quotes 14, 15). In particular, MSM reported disclosure
to family as unlikely due to fear of rejection or being seen as “promiscuous” (Quote 16).
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Concerns about health care professionals—While FSW and TG participants spoke
of the potential lack of sensitivity on the part of health care professionals dispensing PrEP,
they also mentioned that the Peruvian Ministry Of Health was conducting sensitivity
workshops for all health care staff to improve communication and trust with patients of
diverse sexual orientations and risk behaviors (Quotes 17, 18).
PrEP’s ideal characteristics—Accessibility: All three populations preferred PrEP being
available in health care centers as opposed to pharmacies, citing higher costs (Quote 19),
increased potential for patient misuse (Quote 20), and privacy risks (Quote 21) if the drugs
were dispensed in neighborhood pharmacies. Cost: TG and FSW thought that PrEP should
be free like contraception pills given out at Health Centers (Quote 22). Conversely, MSM
felt that PrEP should cost something, citing a risk for habituating the population to
something free which eventually may be charged for (Quote 23), or that paying for PrEP is
part of investing in one’s own health (Quote 24). Duration of use: Acceptability views
ranged from taking PrEP as a time-limited activity dependent on the duration of being a sex
worker (Quote 25), to a lifetime commitment by MSM (Quote 26). Effectiveness: 100%
effectiveness was desired by all three populations (Quotes 27, 28). Frequency of dosing:
Daily dosing was endorsed by FSW who saw it as commensurate with their type of work
(Quote 29), but not by TG or MSM who viewed daily dosing as impractical or incompatible
with a lifestyle where most people “live in the moment” (Quotes 30, 31, 32) Provider: All
groups agreed that PrEP should be delivered by health care professionals, as these were seen
as people who already were interacting with the population, could handle other health
concerns (Quotes 33, 34) and offered the most privacy (Quote 35).
Behavioral changes after PrEP—Only FSW participants felt that PrEP would not
change sexual risk-taking behaviors since it would only protect against HIV and not other
STI’s (quote 36). TG and MSM participants, however, felt that condom use would decrease
as a result of PrEP (Quotes 37, 38, 39).
Conjoint Analysis
PrEP acceptability ranged from 19.8 to 82.5 on the 0-100 point scale, with a mean
acceptability of 53.4 out of 100 across the 8 hypothetical PrEP scenarios. The scenario with
the highest acceptability (scenario 1) had the following attributes: $10 per month, 95%
efficacy, no side effects, 10 years duration of administration, use before sex, and dispensed
at an HIV clinic by a doctor/nurse. Table 3 shows the acceptability of all 8 PrEP scenarios
and their attribute profiles.
Table 4 shows the impact of each of the 7 PrEP attributes on PrEP acceptability, and
acceptability with the preferred versus the non-preferred value of each attribute. Cost had
the single greatest impact on acceptability across the 7 PrEP attributes, controlling for all
other PrEP attributes. Participants reported significantly higher PrEP acceptability with a
cost of $10 (acceptability=62.0), compared to a cost of $250 (acceptability=36.8), yielding a
net impact score of 25.2 (p <.001). Efficacy had the second greatest impact on PrEP
acceptability. Participants reported significantly higher PrEP acceptability with a 95%
efficacious PrEP (acceptability=60.0 out of 100), compared to PrEP with a 75% efficacy
(acceptability=38.7 out of 100), yielding a net impact score of 21.4 (p<.001). Additionally,
side effects had a significant impact on PrEP acceptability. The acceptability of PrEP with
no side effects was 56.7 on the 0-100 point scale, in contrast to the mean score of 42.0 (p <.
001) for PrEP with minor side effects of nausea and dizziness. While not statistically
significant, there was a notable preference for PrEP being dispensed by a health care
professional (vs. pharmacist).
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DISCUSSION
In this convenience sample of FSW, TG and MSM in Peru, we found a wide range of
attitudes and opinions regarding PrEP acceptability. Important potential barriers to PrEP
found in both the focus group and conjoint analysis data included high out-of-pocket cost,
partial efficacy, and fear of side effects. Stigma and discrimination associated with PrEP
use, mistrust of health care professionals, and a belief that PrEP would result in a decrease in
condom use were concerns for MSM and TG. These potential barriers will require careful
attention when planning for PrEP dissemination.
Acceptability of the best possible PrEP scenario (82.5 out of 100) suggests the potential for
widespread use in our target population with an optimal product. Nevertheless, the average
acceptability of 53.4 on the 0-100 scale across the eight hypothetical PrEP scenarios may be
a more realistic estimate of its probable uptake and indicates that the eventual degree of
acceptability of PrEP is likely to be influenced by its specific characteristics.
Both conjoint analysis and focus group data revealed concerns regarding PrEP use. Cost had
the single greatest impact on PrEP acceptability in the conjoint analysis; participants were
significantly more likely to indicate acceptance of PrEP with a low out-of-pocket cost.
Focus group data supported this finding, with some participants expecting PrEP to be free or
low-cost (like contraception pills) while others feared that if PrEP was initially free but then
later charged for use would decrease. Efficacy had the second greatest impact on PrEP
acceptability in the conjoint analysis. Participants were significantly more likely to indicate
acceptance of PrEP with a 95% efficacy than a 75% efficacy. Focus group findings revealed
that 100% efficacy (understandably) was desired by all three study populations, however,
even an optimistic estimate of potential PrEP efficacy places it at 90%,33 thus participant
expectations may be unrealistically high. Side effects such as nausea and dizziness had a
significant impact on PrEP acceptability in the conjoint analysis. Focus group data supported
this finding, with all three populations expressing concerns about the potential side effects of
PrEP particularly with regard to existing health conditions. While not statistically
significant, there was a notable preference for PrEP being dispensed by a health care
professional (vs. pharmacist) in the conjoint analysis. Focus group findings also showed a
preference for PrEP being dispensed by health care professionals (vs. pharmacists). While
all groups voiced concerns about health care professionals that might discourage them from
using PrEP, such fear of being mistreated, lack of sensitivity, and stigma and discrimination
regarding sexual orientation (MSM and TG) and lifestyle (FSW), they maintained that
health care professionals were better qualified than pharmacists to dispense PrEP.
Focus groups revealed some information regarding PrEP characteristics not identified in the
conjoint analysis. For example, all three populations preferred PrEP being dispensed in
health care clinics (vs. pharmacies). In Peru, neighborhood drugstores are numerous and
many are family-operated, thus making privacy a potential issue if PrEP were dispensed at
such establishments. We also found that daily use of PrEP would not be acceptable to MSM
and TG, while FSW seemed more willing to accept PrEP on a daily basis comparing it to an
anti-conception pill also taken daily.
Information regarding social barriers related to the disclosure of PrEP use emerged in the
focus group data. All three populations reported being hesitant to disclose PrEP use with
anyone outside of their social networks, with fears stemming from the potential of stigma
and discrimination that could be associated with their lifestyles or behaviors by parents,
friends or clients. Similar findings have been shown in previous studies.34-35 It is unknown
how social barriers will impact the acceptability of PrEP, but the very fact that it is a
relatively “invisible” prevention method compared to condoms, and could be used without
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others’ knowledge may in fact be considered an important potential strength of PrEP as an
HIV prevention strategy.
One issue we hoped to assess in this study was the possible impact of PrEP on behavioral
risk disinhibition. Concerns regarding risk disinhibition hypothesize that new HIV
prevention technologies like PrEP may foster an overly optimistic sense of protection among
users and lead to increased risk behaviors (e.g., by reduced condom use; feelings of
“immunity” to HIV, etc.).34-36 The data for MSM and TG in our study suggest that this was,
in fact, a concern but interestingly not for FSW. While this discrepancy requires further
exploration, it is possible that FSW may view PrEP specifically as added security against the
occupational hazards of their work.
There were limitations to our study. First, we chose focus groups as one of our methods to
explore PrEP acceptability. This methodology facilitates in-depth discussion of individual
perspectives within the context of a larger group but may over represent specific participant
contributions; therefore, aggregate group data may not reflect equally the specific concerns
of every group participant. Second, the small sample size (n = 45), convenience sampling,
and selection bias limits the ability to generalize our results to others. The purpose of this
study was to elicit and explore reactions to hypothetical PrEP among select consumers at
potential risk for HIV rather than to generalize our findings to all persons at risk. Third, the
variables modeled in the conjoint analysis included physical characteristics of PrEP. We
consulted PrEP experts in creating 7 of the most critical characteristics of PrEP, which was
based on current knowledge at the time the study was conducted. Social issues (e.g.,
perception of HIV risk, HIV testing practices, relationship issues, trust in providers, stigma/
discrimination,37-39 and social saturation40) were not included in the model, and may also
impact PrEP acceptability. Further investigation of the impact of social issues on PrEP
acceptability using conjoint analysis is warranted. Finally, it is important to note that
conjoint analysis need not reflect the exact characteristics of a future PrEP to yield
meaningful data. Rather, the purpose is to present a meaningful range to consumers within
each PrEP attribute in order to estimate the likely impact of PrEP attributes on product
acceptability.23,27
PrEP studies are underway, and within the next few years efficacy data will begin to emerge.
With hope and scientific data mounting, it is essential to prepare for the possible roll-out of
PrEP should it be shown to be efficacious. Our study demonstrated that clear differences
were observed between groups, particularly the FSW versus the TG and MSM, pointing to
the necessity of much deeper exploration of the intended target groups in each environment
-- or microenvironments -- where PrEP is introduced.
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Table 1
Focus Group Interview Guide
# Questions Probes
1 PrEP in general
What have you heard about antiretroviral
medication used for HIV prevention (PrEP)?
Examples, analogies
• Like malaria prophylaxis
• Like contraception
2 What do you know about PrEP or about how it
works?
• Understand that PrEP is before you are exposed, like a vaccine,
different from PEP, that you take after you are exposed, like the
morning after pill.
3 How would you feel about taking a medication
everyday to prevent HIV infection?
Possible issues:
• Remembering to take it
• Finding a place to get it
• Finding someone to prescribe it
• People seeing you take it
4 Receptiveness to PrEP and explanation
Would you or your close friends be willing to
take PrEP?
• Do you think your friends would be (very likely, somewhat
likely, somewhat unlikely or not likely) to take PrEP?
5 What would be the reasons you or your close
friends would want to take PrEP?
• To protect against getting ill from HIV?
• So you or your close friends could have unprotected sex?
6 What would be the reasons you or your close
friends would NOT want to take PrEP?
• Fears, worries, barriers
7 Social and community concerns
What are possible social concerns that may
discourage you or your close friends from
taking PrEP?
• Stigma
• Discrimination
• Disclosure
• What would your family think?
• What would your acquaintances think?
• What would your sexual partners think?
• Any other possible social or community concerns?
8 Health Care Provider concerns
What are possible concerns about health care
providers that may discourage you or your
close friends from taking PrEP?
• People recognizing you when you get the meds
• Provider judging you
• Difficulty accessing it
• Difficulty getting information
• Being embarrassed to ask for it from providers
9 PrEP Characteristics
• Side effects
• Places (where) of dissemination
• Person who dispenses
• Duration of taking PrEP
• Effectiveness
• Frequency of administration (QD vs. before
sex acts)
• Nausea, vomiting
• Pharmacy, doctor’s office, HIV clinic
• Pharmacist, doctor or other professional
• Days, weeks, years, lifetime
• What percentage of effectiveness should PrEP have in order for
people to use it?
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# Questions Probes
• Cost
10 Behavioral change after PrEP
• How would having PrEP available change
your or your friends’ sexual behaviors?
• How would taking PrEP change your or
your close friends’ use of condoms?
• How much might they change their behaviors? (A little? A lot?
Not at all?)
• How would taking PrEP or having it available change your or
your close friends’ use of condoms? (A little? A lot? Not at all?)
• Are there things we might be able to tell your friends to prevent
them from increasing their risk behaviors if PrEP were
available? What might we say?
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Table 2
Representative Quotes from Target Populations
Theme Representative Quotes Group
1. Awareness 1. “Well, I have heard about it through a [local NGO]…they talked about some pre-exposure pills studies. And I
know it was an
antiretroviral and I know it is being used as a treatment.”
TG
2. Attitudes/
Expectations
2. “I think that if you put it right next to your night table, when you go to bed, for you to take it next to the night
table, with your
little glass of water and take it.”
FSW
3. “I think that at the beginning yes, a week and that, but from there on out, they won’t take it and that’s that.” TG
4. “Well, if I am a person who has continuous [sexual] relationships yes, I’d take it, but if I don’t…why would I
take it?”
MSM
5. “…there’s also some people who suffer from high blood pressure, or who are diabetic, so [an exam would be
necessary]…so that
that kind of problem won’t exist with the pills.
FSW
6. “If it’s going to have a lot of side effects in my body, I would leave it, I wouldn’t accept it.” TG
7. “…on Saturdays, if you have a party let’s say, you know you are going to drink and then you don’t take the
pill.”
MSM
8. “…well we will take care of ourselves and see that everyone takes it, because if we get infected we could
infect others.”
FSW
9. “It would be good when I am drunk and suddenly I don’t use the condom or it breaks.” TG
10. “I think that most of my friends are going to want to take it…and be more secure when a “one-night stand”
appears.
MSM
3. Social/
Community
Concerns
11. “I may tell the ones who are in this business, but not to others who aren’t.” FSW
12. “I would tell my transvestite friends about the treatment.” TG
13. “If I tell you that I am starting to take PREP, I would say that it is my own caring about myself, something
which is only mine.”
MSM
14. [“I would not tell my clients”]… because they may feel scared. FSW
15. “If it is just a “one-night stand”, no.” MSM
16. “I think that there would be some kind of rejection from my family…they would think I am a promiscuous
person.”
MSM
4. Concerns
about health
care
professionals
17. “There is an order from [the Public Health Department to conduct] workshops for all the personnel…because
complaints were
received from girls who had been psychologically mistreated.
FSW
18. “It’s because of the stigma that they have with us, because we are transvestites, because gays and sex workers
have HIV. There
are still medical personnel who keep on thinking like that and with that discrimination, they aren’t mentally
skilled to treat us.”
TG
5. PrEP’s ideal
characteristics
19. “In the health center, because medicines are usually of the same quality and they are a little bit cheaper. In the
drugstores, there
are differences between one and the other; you have to look for the cheapest…
FSW
20. “…if it were available at any drug store, there could be people who misuse it…and they wouldn’t take care of
themselves.”
TG
21. “…better in the Health Center, because sometimes people don’t go to the drugstores…in their
neighborhood…because they are
afraid of being identified as a person who has sexual relationships.”
MSM
22. “[I prefer that they are free]… that they are like the contraception pill they give us in the health centers.” FSW
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Theme Representative Quotes Group
23. “[If free]…they would get used to have it for free all the time and when it is unavailable, they just won’t buy
it.”
MSM
24. “Yes, of course [I would pay for PrEP]…something that says that at least I am paying some of my own
money…for my health.”
MSM
25. “I think that [I would use it] until I stop working.” FSW
26. “To me, forever, because if I have a sexual intercourse I need it. But I would take it all my life while I have
sexual activity….”
MSM
27. “A hundred percent.” TG
28. “It would have to be 100% effective, I think that everyone would demand 100%” MSM
29. “[Every day] because you go to work but if you don’t work, you have to take it the same, yes everyday…” FSW
30. “I think that it wouldn’t work taking the pills every day because most people are not like that…they live in
the moment. But the
idea of taking it once a month, or every three months. I think that they could do it as if it were a contraceptive
pill.”
TG
31. “If they ask me to choose, I’d rather have it weekly or twice a week, by tablet, by capsule, by shot or
whatever, it is far more
likely than doing it daily.”
MSM
32. “When you are in the moment having sex, you forget and then suddenly you don’t take it…you’re not going
to be carrying your
little bag with your pill in it [laughs] at the disco!”
MSM
33. “Yes, but it could also be through the psychologist who talks to us, orientates us and gives us information.” FSW
34. “…your doctor or your counselor is going to tell you something or ask you questions like, ‘How are you
feeling? How has your
body reacted?’ I think that is a good thing and it should be like that too.”
TG
35. “I think that it should be right there with the doctor or the counselor who delivers the pills directly. It should
be the doctor
because you enter his office and nobody knows what you are there for.”
MSM
6. Behavior
changes after
PrEP
36. “[Behaviors would not change], because that is only for HIV.” FSW
37. “I think that they would take the pills but they wouldn’t use the condom anymore.” TG
38. “If you tell someone, ‘Look, take this pill and it will prevent you from getting HIV,’ I can assure you that the
next day, that
person won’t use a condom anymore.”
MSM
39. “There should be a lot of information and say that it is something additional to the condom and which is
going to give you some
extra protection;…if you tell them that [PrEP] is 100% secure, they won’t use [a condom] anymore.”
MSM
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Table 4
Impact of Pre-Exposure Prophylaxis (PrEP) attributes on hypothetical PrEP
acceptability in Peru (n=45)
PrEP Attribute values
Acceptability of PrEP
with preferred attribute
(mean)
Acceptability of PrEP
with non-preferred attribute
(mean)
Impact on PrEP
acceptability
Mean (SD)a
Cost per month* $10 vs. $250 61.92 36.77 25.15(29.30)
Effectiveness* 95% vs. 75% 60.03 38.66 21.37(26.31)
Side Effects* none vs. nausea/dizziness 56.69 42.01 14.68(30.95)
Duration of
 administration 1 year vs. 10 years 48.55 50.15 −1.60(19.39)
Frequency before sex vs. every day 48.55 50.15 −1.60(20.60)
Location PrEP is
 dispensed general clinic vs. HIV clinic 48.40 50.29 −1.89(22.64)
Person dispensing
 PrEP pharmacist vs. doctor/nurse 47.67 51.02 −3.34(13.46)
*
p <0.001 for one sample t-tests
a
SD = Standard Deviation
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